DNB Asset Management AS Acquires 154,954 Shares of BioMarin Pharmaceutical Inc. $BMRN

DNB Asset Management AS increased its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 13.8% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 1,274,284 shares of the biotechnology company’s stock after purchasing an additional 154,954 shares during the period. DNB Asset Management AS owned approximately 0.66% of BioMarin Pharmaceutical worth $69,015,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BMRN. Quent Capital LLC acquired a new position in shares of BioMarin Pharmaceutical during the third quarter worth approximately $28,000. Smartleaf Asset Management LLC raised its stake in BioMarin Pharmaceutical by 92.5% during the 3rd quarter. Smartleaf Asset Management LLC now owns 749 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 360 shares during the last quarter. Hantz Financial Services Inc. boosted its holdings in BioMarin Pharmaceutical by 480.2% in the 2nd quarter. Hantz Financial Services Inc. now owns 1,056 shares of the biotechnology company’s stock valued at $58,000 after purchasing an additional 874 shares during the period. Employees Retirement System of Texas acquired a new stake in BioMarin Pharmaceutical in the 2nd quarter worth $58,000. Finally, Jones Financial Companies Lllp increased its holdings in shares of BioMarin Pharmaceutical by 88.1% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,401 shares of the biotechnology company’s stock worth $75,000 after purchasing an additional 656 shares during the period. Institutional investors and hedge funds own 98.71% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on BMRN. Tudor Pickering set a $88.00 target price on BioMarin Pharmaceutical in a research report on Monday, November 3rd. Piper Sandler lowered their price objective on BioMarin Pharmaceutical from $122.00 to $84.00 and set an “overweight” rating on the stock in a research report on Friday, February 6th. Stifel Nicolaus set a $68.00 target price on BioMarin Pharmaceutical in a research note on Tuesday. HC Wainwright lowered their price target on shares of BioMarin Pharmaceutical from $60.00 to $55.00 and set a “neutral” rating on the stock in a report on Wednesday. Finally, Barclays began coverage on shares of BioMarin Pharmaceutical in a research note on Wednesday, January 28th. They issued an “overweight” rating and a $80.00 price objective for the company. Fifteen investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $87.71.

BioMarin Pharmaceutical Stock Performance

BioMarin Pharmaceutical stock opened at $61.11 on Friday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.21 and a quick ratio of 3.10. The stock has a fifty day moving average price of $58.90 and a two-hundred day moving average price of $56.15. BioMarin Pharmaceutical Inc. has a 52-week low of $50.76 and a 52-week high of $73.51. The firm has a market capitalization of $11.74 billion, a P/E ratio of 34.33, a P/E/G ratio of 0.52 and a beta of 0.26.

Insider Activity

In related news, EVP Gregory R. Friberg sold 6,326 shares of the stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $60.38, for a total transaction of $381,963.88. Following the completion of the sale, the executive vice president owned 37,578 shares in the company, valued at $2,268,959.64. This trade represents a 14.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.85% of the stock is owned by company insiders.

BioMarin Pharmaceutical News Summary

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Wells Fargo called BMRN an attractive buy ahead of the Transcon‑CNP PDUFA, signaling investor interest around the upcoming regulatory decision. Wells Fargo Buy Note
• Positive Sentiment: Sanford C. Bernstein raised its price target from $90 to $94 and kept an outperform rating — a direct positive signal from a major sell‑side shop. Bernstein PT Raise (Benzinga)
• Positive Sentiment: Analysis pieces argue that recent share rebound and DCF assumptions may still imply upside for BMRN, supporting a constructive view for longer‑term investors. Pricing / DCF Upside Analysis
• Neutral Sentiment: Analysts broadly revised forecasts after Q4 results; the coverage is mixed and driving headline activity but not a uniform consensus. Analyst Revisions (Benzinga)
• Neutral Sentiment: BioMarin’s Q4 earnings call highlights were released; investors will parse guidance and R&D updates for implications on cash runway and upcoming catalysts. Q4 Earnings Call Highlights
• Neutral Sentiment: Short‑interest reports flagged a “large increase,” but the filings in the feed show inconsistent/zero values (NaN/0), making the short‑interest signal unreliable for now; not a clear driver.
• Negative Sentiment: HC Wainwright cut its price target to $55 and moved to a neutral rating, a downgrade that reduces near‑term sentiment given the lower target relative to recent levels. HC Wainwright PT Cut (Benzinga)
• Neutral Sentiment: Guggenheim trimmed its target from $106 to $86 but kept a buy rating; Oppenheimer also lowered its target to $95 — mixed signals that compress consensus and increase short‑term volatility. Guggenheim / Oppenheimer Coverage (Benzinga / AmericanBankingNews) Read More.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.